Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mari Shiomi"'
Autor:
Minami Ohara, Harumi Takahashi, Ming Ta Michael Lee, Ming-Shien Wen, Tsong-Hai Lee, Hui-Ping Chuang, Chen-Hui Luo, Aki Arima, Akiko Onozuka, Rui Nagai, Mari Shiomi, Kiyoshi Mihara, Takashi Morita, Yuan-Tsong Chen
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105891 (2014)
UNLABELLED:To clarify pharmacokinetic-pharmacodynamic (PK-PD) factors associated with the over-anticoagulation response in Asians during warfarin induction therapy, population PK-PD analyses were conducted in an attempt to predict the time-courses of
Externí odkaz:
https://doaj.org/article/0a21cceacd444132bbc93c091cc0ed42
Publikováno v:
Journal of Infection and Chemotherapy. 29:592-598
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab35f7f58bfac9fcc7bc79297c87f69f
https://doi.org/10.1016/j.jiac.2023.02.012
https://doi.org/10.1016/j.jiac.2023.02.012
Autor:
Mari Shiomi, Kajal B. Larson, Matthew L. Rizk, Makoto Kakara, Hiroyuki Yoshitsugu, Hwa-Ping Feng
Publikováno v:
Journal of Infection and Chemotherapy. 25:182-191
Tazobactam/ceftolozane is a combination of a β-lactamase inhibitor and a cephalosporin antibiotic, with recommended dosage for patients with normal renal function of tazobactam 0.5 g/ceftolozane 1 g administered as a 1-h intravenous infusion every 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3e5a72f948f7e8182440a4564dc2c
https://doi.org/10.1016/j.jiac.2018.11.005
https://doi.org/10.1016/j.jiac.2018.11.005
Autor:
Atsushi Ikeda, Miyuki Kimura, Tomohiro Ishikawa, Yuji Kumagai, Shin Irie, Noriaki Nishino, Mari Shiomi, Shunji Matsuki
Publikováno v:
Clinical Pharmacology in Drug Development. 4:218-225
This randomized, two-way crossover study evaluated the bioavailability of elvitegravir administered as the new individual tablet containing 150 mg and a cobicistat 150 mg tablet, concomitantly with a fixed-dose combination tablet containing 200 mg of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89a31ab455231a6d19064fc4e8a3b6ae
https://doi.org/10.1002/cpdd.164
https://doi.org/10.1002/cpdd.164
Autor:
Fumio Nagashima, Hiroyasu Iwasa, Wataru Ichikawa, Yasushi Okazaki, Ken-ichi Fujita, Takashi Hirose, Toshimichi Miya, Yuko Akiyama, Kazuhiro Araki, Mari Shiomi, Masaru Narabayashi, Kaori Kawara, Yuichi Ando, Hiroyasu Ogata, Hisashi Endo, Yu Sunakawa, Wataru Yamamoto, Keiji Kodama, Yasutsuna Sasaki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 65:251-258
To investigate the effects of genetic polymorphisms on morphine-induced adverse events in cancer patients. We examined the relation of morphine-related adverse events to polymorphisms in UDP-glucuronosyltransferase (UGT) 2B7, ATP-binding cassette, su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9415bda681ce4a404e18c35b1232ac61
https://doi.org/10.1007/s00280-009-1029-2
https://doi.org/10.1007/s00280-009-1029-2
Autor:
Tomoo Funaki, Mari Shiomi
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 33:117-126
Nonlinear Mixed-Effects Methods for S-PLUS (Mixed-effects modeling function-version 3.3 NLME) have been reported. A zero-order infusion model was created for NLME in this study. Data from the literature for trastuzumab were used for analysis with the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e82424468fd0a4d7c6ceb9fdee7086be
https://doi.org/10.3999/jscpt.33.4_117
https://doi.org/10.3999/jscpt.33.4_117
Autor:
Yuan-Tsong Chen, Takashi Morita, Hirotoshi Echizen, Michael T. M. Lee, Yosuke Ichimura, Mari Shiomi, Harumi Takahashi, Kiyoshi Mihara
Publikováno v:
Clinical pharmacokinetics. 51(12)
Genetic polymorphisms of cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) and patient demographic characteristics are responsible for inter-individual differences in warfarin maintenance dosage requirement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0add6f2354b933495f546203a4c5897d
https://pubmed.ncbi.nlm.nih.gov/23018470
https://pubmed.ncbi.nlm.nih.gov/23018470
Autor:
Masahiro Kaneko, Masako Saito, Tetsuya Sumiyoshi, Mari Shiomi, Hiroyasu Ogata, Junichi Kawana, Masatoshi Nagayama, Kiyoshi Mihara, Kazuhiko Hanada, Tetsuro Ohno
Publikováno v:
Biologicalpharmaceutical bulletin. 33(8)
Carvedilol is a beta-adrenoceptor antagonist used for treating chronic heart failure (CHF). Two clinical studies were conducted to evaluate the population pharmacokinetics and pharmacodynamics of R- and S-carvedilol, and associated covariates, in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c26dd7f39605d54c90c4c0be7ecfc4a
https://pubmed.ncbi.nlm.nih.gov/20686235
https://pubmed.ncbi.nlm.nih.gov/20686235
Autor:
Nobuo, Sato, Hisashi, Suzuki, Hiroyuki, Hayashi, Shigeki, Shibasaki, Toshie, Sugano, Kazunori, Maebashi, Tohru, Kurosawa, Mari, Shiomi, Hiroyasu, Ogata
Publikováno v:
The Japanese journal of antibiotics. 61(5)
Pharmacodynamic (PD) characterization (concentration-dependent, time-dependent, etc.) of antibiotics is determined by aspects of the pharmacodynamic interaction between antibiotics and microorganisms. There are three major aspects of the pharmacodyna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f873381b4aa486fc5cf7ff35e211fae
https://pubmed.ncbi.nlm.nih.gov/19260351
https://pubmed.ncbi.nlm.nih.gov/19260351
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 0306474719
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc0fde301a3bf4da1b31df74a43c20d8
https://doi.org/10.1007/0-306-47932-x_4
https://doi.org/10.1007/0-306-47932-x_4
